Table 5CADTH Reanalysis (OnabotulinumtoxinA vs. Topiramate)

AnalysisComparatorCost ($)QALYsICUR ($ per QALY Gained)
Manufacturer’s scenario analysisOna A7,2831.60-
Topiramate3,4931.35-
Incremental3,3390.2513,283
CADTH topiramate comparison scenario analyses
T11c, 2a, 3, 4c, 5, 6, and no adverse-event disutilities*Ona A7,7991.86-
Topiramate4,1511.74-
Incremental3,6480.1328,968

CM = chronic migraine; ED = emergency department; EQ-5D = EuroQol 5-Dimensions questionnaire; EM = episodic migraine; HDPM = headache days per month; HIT-6 = six-item Headache Impact Test; ICUR = incremental cost-utility ratio; ITT= intention-to-treat; MSQ = Migraine-Specific Quality of Life Questionnaire; Ona A = onabotulinumtoxinA; QALY = quality-adjusted life-year.

*

See Table 18 for the results of the reanalyses that were incorporated.

From: Information on the Pharmacoeconomic Submission

Cover of Pharmacoeconomic Review Report: OnabotulinumtoxinA (Botox)
Pharmacoeconomic Review Report: OnabotulinumtoxinA (Botox): (Allergan Inc.): Indication: For the prophylaxis of headaches in adults with chronic migraine (≥ 15 days per month with headache lasting four hours a day or longer) [Internet].
Copyright © 2019 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.